Amgen profit beats estimates, weight-loss data due by year-end
Update: 2025-11-04
Description
Amgen's Q3 financial results exceed expectations, with a 12% revenue increase to $9.56 billion and a 1% rise in adjusted earnings per share to $5.64. Repatha sales surge by 40%, while Enbrel sales drop by 30% due to price changes. Amgen is optimistic about MariTide, their new weight-loss drug, with key data expected by year-end. The company raises its full-year financial outlook, projecting adjusted earnings between $20.60 and $21.40 per share and revenue between $35.8 billion and $36.6 billion.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
